A study testing whether a GLP-1 medicine, semaglutide, can help people with mobility disability lose weight.
Recruiting now. Registry record last updated July 1, 2026.
- Who can join
- Adults 65 to 100, have obesity or are overweight, BMI 35+.
- What you take
- semaglutide, given as part of the study. Check ClinicalTrials.gov for this trial's study groups, including any placebo or comparison medicine.
- How long it lasts
- The full study runs about 1.8 years; your own time in it is usually shorter.
- What you get
- Many clinical trials pay for the study medication and the study visits. Some also pay for travel. Ask the study team what this one covers before you sign the consent form.
What this study is for
Primary condition: Obesity & Overweight. Also studied in: Mobility Disability, HOMA-IR.
Full scientific study title: Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist.
Who can join
Adults 65 to 100, have obesity or are overweight, BMI 35+. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.
Full medical eligibility (for you and your doctor)verbatim from the registry
This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.
Key inclusion criteria
- Subjects accepted for this study must:
- Provide informed consent from the subject or the subject's legally authorized representative
- Be able to communicate effectively with the study personnel
- Be ≥65 years of age at the time of screening
- For Female Subjects Menopausal status
Key exclusion criteria
- Known hypersensitivity or allergy to enobosarm or a GLP-1 receptor agonist
- Estimated glomerular filtration rate (eGFR) \< 30 mL/min/1.73 m2 as measured using the chronic kidney disease-epidemiology collaboration (CKD-EPI) calculation (patients with mild and moderate renal failure are not excluded from participation in this study)
- Treatment with any investigational product within \< 5 half-lives for each individual investigational product OR within 30 days prior to randomization
- Major surgery (the surgery poses a significant risk to patients life and requires general anesthesia) within 30 days prior to randomization
- Planned major surgery during the course of the study or any cosmetic surgery potentially impacting body composition, e.g., liposuction, implants, or removal of any current implants
Where this trial is enrolling
This trial has 14 sites across 10 states. Contact a site coordinator directly to start screening.
Arizona1 site
- DM Clinical Research - PhoenixPhoenix, Arizona
Florida5 sites
- DM Clinical Research - MIADoral, Florida
- Universal Axon Clinical Research (Rovia - UACR)Doral, Florida
- Paramo HealthMiami, Florida
- IMIC Research a Rovia Clinical Research CompanyMiami, Florida
- Paramo HealthMiami, Florida
Georgia1 site
- UD ResearchAtlanta, Georgia
Louisiana1 site
- Pennington Biomedical Research CenterBaton Rouge, Louisiana
Maryland1 site
- Centennial Medical Group (CMG)Columbia, Maryland
Mississippi1 site
- SKY Integrative Medical CenterRidgeland, Mississippi
New York1 site
- ALSA ResearchNew York, New York
North Carolina1 site
- Coastal Research Institute, LLCFayetteville, North Carolina
Texas1 site
- DM Clinical - DallasIrving, Texas
Washington1 site
- DM Clinical - SeattleSeattle, Washington
Timeline
Started enrolling: March 26, 2026. Expected completion: December 2027. Last updated on ClinicalTrials.gov: July 1, 2026.
Official source
Every Monday we check this trial against ClinicalTrials.gov, the federal registry for clinical research. Last checked August 29, 2026. Confirm the current status there before you contact a site:
Other GLP-1 clinical trials
Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.
